Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can functi...

Full description

Bibliographic Details
Main Authors: Deirdre Kelly, Anna Spreafico, Marcus O Butler, David Hogg, Danny Ghazarian, April A N Rose, Thiago Pimentel Muniz, Samuel D Saibil, Susan M Armstrong, Diana P Arteaga, Ian King, Zaid Saeed Kamil, Kendra Ross
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/1/e001642.full

Internet

https://jitc.bmj.com/content/9/1/e001642.full

Similar Items